Catalog No.
DHC01301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Transthyretin, Prealbumin, TBPA, TTR, PALB, ATTR
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P02766
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
NI-301, NI 301, NI301
Clone ID
NI-301
Note
For research use only. Not suitable for clinical or therapeutic use.
Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissue., PMID:34428239
Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment., PMID:34443678
[Heart damage in the combined types of systemic amyloidosis]., PMID:34609800
Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution., PMID:34653913
Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease., PMID:34814699
Developing Therapy for Transthyretin Amyloidosis., PMID:35077703
Cardiac microcalcifications in transthyretin (ATTR) amyloidosis., PMID:35077727
Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist., PMID:35325395
Cardiac Amyloidosis Treatment., PMID:35414852
Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges., PMID:35456241
Dual Targeting of Soluble Oligomeric and Aggregated Transthyretin with a Monoclonal Antibody Ameliorates Experimental Neuropathy., PMID:36290413
Current approaches to the diagnosis and management of amyloidosis., PMID:36478370
Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria., PMID:36621346
Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis., PMID:36795075
Treatment of amyloidosis: present and future., PMID:37091663
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid., PMID:37212440
Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy., PMID:37285532
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures., PMID:37439769
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease., PMID:37470509
Strong positive light chain immunostaining in a patient with transthyretin amyloidosis., PMID:37551718
Coronary artery bypass grafting for triple vessel disease in cardiac amyloidosis., PMID:37699742
Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion., PMID:37854603
Randall-Type Monoclonal Immunoglobulin Deposition Disease in Bone Scintigraphy., PMID:37883135
Pathomorphological Features of the Novel Coronavirus Disease in Patients with Systemic Amyloidosis., PMID:37893183
Epidemiological study of the subtype frequency of systemic amyloidosis listed in the Annual of the Pathological Autopsy Cases in Japan., PMID:38088470
Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy., PMID:38184468
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy., PMID:38233673
Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer., PMID:38359019
Treatment of transthyretin cardiac amyloidosis., PMID:38652263
Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis., PMID:38801321
Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment., PMID:38809394
Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis., PMID:38844305
Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients., PMID:39029855
Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis., PMID:39086890
[Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report]., PMID:39106513
Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis., PMID:39338387
Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling., PMID:39410666
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study., PMID:39472768
Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances., PMID:39551565
Optimizing drug therapies in cardiac amyloidosis., PMID:39586360
Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022., PMID:39592278
Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis., PMID:39627935
Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications., PMID:39714070
Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation., PMID:39775625
New therapies to treat cardiac amyloidosis., PMID:39819772
Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies., PMID:39841315
Concurrent Therapy for Immunoglobulin Light Chain Cardiac Amyloidosis and Transthyretin Cardiac Amyloidosis: A Case Report., PMID:39924245
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions., PMID:40232627
Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy., PMID:40335224
Current and emerging treatment options for transthyretin amyloid cardiomyopathy., PMID:40425273
For research use only. Not for human or drug use.
